Kamada off premarket

Shares of Kamada (KMDA) are off 30% in premarket trading on high volume in response to its report on its AAT clinical trial. Results were a bit of a mixed bag highlighted by a failure to achieve the primary endpoint.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs